SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected fourth-quarter outlook, alongside slowing PC demand linked to high memory costs and supply bottlenecks, drove the sharp selloff despite stronger data-center growth. Traders are split between viewing the outlook as evidence of deeper execution problems and seeing the decline as an overreaction and a buying opportunity.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

A reported major Binance security breach and suspended withdrawals have fueled a crypto-wide selloff, with traders debating whether the incident signals broader risks to Bitcoin or is limited to an exchange. Some see the drop as a buying opportunity and argue Bitcoin itself was not hacked, while others warn of further losses and weakened confidence in crypto.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons earnings miss and heavy AI infrastructure spending, which drove free cash flow negative, sparked a sharp selloff despite accelerating AWS growth. Traders are debating whether the cloud business can justify the spending, with some viewing the reaction as an overreaction and others questioning the returns on AI investment.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated lifileucel lung-cancer data triggered a sharp selloff: the overall response rate was broadly unchanged, while a retrospective biomarker-selected subgroup showed a much higher response rate. Traders are divided between viewing the subgroup as a promising precision-treatment strategy and worrying about immature durability data, regulatory uncertainty, and managements confusing presentation.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

A weaker-than-expected Q4 outlook, declining Google search referrals and softer U.S. user numbers overshadowed Reddits strong Q3 results, driving a sharp selloff; the planned logged-in-only browsing shift has added concern about losing casual traffic. Traders are split between viewing the drop as an overreaction and seeing the traffic and user trends as a longer-term growth risk.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

Rumors and reports of a major Binance security breach are driving attention, with traders citing potential large crypto losses and frozen assets while questioning the safety of exchange-held funds. Some fear the incident could deepen selling or raise insolvency concerns, while others dismiss it as shakeout speculation; the claims remain unconfirmed in the discussion.

Pinterest, Inc. engages in the operation of an AI-powered visual search and discovery platform. It enables users to find inspiration, curate ideas, search for products, and discover content through visual recommendations. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is under pressure after its quarterly revenue and earnings fell short of expectations and its next-quarter revenue outlook implied slower growth, prompting concern about advertising monetization and cross-border spending. Traders are split between viewing the record user growth and rising ad impressions as signs of resilience and seeing weaker ad pricing and higher costs as reasons for caution.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is drawing attention amid a cybersecurity-sector pullback linked to Fortinets post-earnings selloff, with traders describing CRWDs decline as sympathy selling rather than a company-specific development. The steep valuation after a major run fuels debate: some traders see a buying opportunity given continued security demand, while others expect further downside.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto is under pressure as Fortinets sharp post-earnings selloffamid concerns about its service-revenue outlookspills over into cybersecurity peers. Traders describe the move as sympathy selling, while others point to the sectors high valuations as a reason for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader AI and semiconductor selloff as investors question whether hyperscalers heavy AI spending will generate adequate returns, with weak Amazon and Intel results and Alphabets decline weighing on tech sentiment. Traders are divided between seeing an AI-bubble or circular-financing risk and arguing that continued cloud growth and infrastructure spending support chip demand; reports alleging China-related ties to CEO Jensen Huang are another source of concern, though Nvidia has disputed the claims.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.read more...

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In 

Equity

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer  

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses 

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

NTHI Heads into Wednesday with a Rare Biotech Convergence: Brain-Cancer Data, Tight Float, and Analyst Targets

DENVER, Colo. ( 247marketnews.com ) — NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock tr...

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer 

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">Moderna</a> and Merck will present Phase 3 melanoma findings on Saturday for their personalized cancer treatment combined with Keytruda.</li><li>Arcus will share Casdatifan kidney-cancer data on Tuesday, while Achieve presents yearlong smoking and vaping cessation findings.</li><li>TG Therapeutics and Kyverna will present CAR-T findings in neurological diseases, including progressive multiple sclerosis.</li></ul><p>The biotech spotlight will move from kidney cancer to Huntington’s disease and personalized cancer treatment this week, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) deliver clinical updates amid a busy schedule of earnings and medical conferences.</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 3% last week, outperforming the<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which fell 2%, and the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, down 6%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> declined 2.2%, trailing SPY but holding up better than QQQ, while the<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> dropped 6%.</p><p><img src="https://news.stocktwits-cdn.com/pharma_pulse_14c016fc9d.png" alt="pharma pulse.png"></p><p>&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.19</td><td>EPRX / UEG Week</td><td>Oral presentation on tissue changes following EP-104GI treatment in eosinophilic esophagitis</td></tr><tr><td>Oct.19</td><td>IMTX / TNGX / ORIC</td><td>Scheduled publication of regular ESMO abstracts</td></tr><tr><td>Oct.20</td><td>RCUS</td><td>New ARC-20 Casdatifan kidney-cancer finding and investor event&nbsp;</td></tr><tr><td>Oct.20</td><td>ACHV / CHEST</td><td>Presentation of 52-week ORCA-OL Cytisinicline efficacy data</td></tr><tr><td>Oct.20</td><td>RGNX</td><td>Sura-vec wet-AMD investor event&nbsp;</td></tr><tr><td>Oct.21</td><td>ABT / DHR / TMO</td><td>Q3 results</td></tr><tr><td>Oct.21</td><td>KYTX / IMUX</td><td>Stiff person syndrome and progressive MS presentations</td></tr><tr><td>Oct.22</td><td>RHHBY / ARGX</td><td>Roche’s quarterly sales update and Argenx’s results</td></tr><tr><td>Oct.22</td><td>VERA / HUMA</td><td>Origin 3 kidney-disease analysis and interim Phase 3 dialysis-access findings</td></tr><tr><td>Oct.22</td><td>TGTX / ZBIO</td><td>Briumvi, Obexelimab and Orelabrutinib presentations</td></tr><tr><td>Oct.23</td><td>ALNY / TGTX / KYTX</td><td>Huntington’s disease and progressive-MS clinical updates</td></tr><tr><td>Oct 23</td><td>TNGX</td><td>Pancreatic-cancer investor webcast</td></tr><tr><td>Oct.23</td><td>IMTX / BHVN / CATX</td><td>Early-stage cancer-treatment presentations at ESMO</td></tr><tr><td>Oct.24</td><td>MRNA / MRK / CMPX / IMTX</td><td>Melanoma, biliary tract cancer and Prame-program findings</td></tr><tr><td>Oct.24</td><td>VERA / MAZE / CLYM</td><td>Clinical presentations at ASN Kidney Week</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Arcus And Achieve Lead Early Data Watch</strong></h2><p>Arcus Biosciences (RCUS) will present kidney-cancer findings on Tuesday from its ARC-20 study of Casdatifan. The update covers initial treatment combinations: Casdatifan plus Cabozantinib in 43 previously treated patients, and Casdatifan alone in 121 more heavily treated patients. Median follow-up is about 21 months for the Cabozantinib combination and 28 months for Casdatifan alone.</p><p>Achieve Life Sciences (ACHV) will present year-long Cytisinicline findings on Tuesday at CHEST in Phoenix. The ORCA-OL study enrolled 475 adults who smoked or vaped and received the drug alongside behavioral support. Results include lab-confirmed measures of quitting. Achieve plans to resubmit its smoking-cessation application in the fourth quarter after a June FDA rejection that the company said concerned manufacturing and labeling, with no clinical efficacy or safety deficiencies identified.</p><p>Eupraxia Pharmaceuticals (EPRX) will present on Monday at UEG Week in Barcelona on tissue changes following EP-104GI treatment for eosinophilic esophagitis, an inflammatory condition that can make swallowing difficult. The findings come from the early, open-label Resolve study, while interim results from its randomized Phase 2b portion are expected in December.</p><p>RegenXBio (RGNX) will review its sura-vec treatment for wet age-related macular degeneration at a Tuesday investor event ahead of trial results expected in the fourth quarter.</p><h2 class="st-heading-2"><strong>Roche And Argenx Take Results Spotlight</strong></h2><p>Roche (RHHBY) will report third-quarter sales on Thursday. First-half sales grew 6%, excluding currency effects but fell 2% in Swiss francs. Growth was led by Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo.</p><p>Argenx (ARGX) also reported on Thursday, following positive Phase 2 findings for its celiac-disease treatment FB102 and its decision to stop its Phase 3 Sjogren’s disease trial after an interim analysis indicated it was unlikely to succeed. Abbott (ABT), Danaher (DHR) and Thermo Fisher Scientific (TMO) report on Wednesday.</p><h2 class="st-heading-2"><strong>Neurological CAR-T Studies In Focus</strong></h2><p>TG Therapeutics (TGTX) will present its first Phase 1 Azer-cel results in primary progressive multiple sclerosis (MS) on Friday at MSToronto2026, with the full abstract due Wednesday. The treatment uses genetically modified donor immune cells. Other presentations cover seven-year Briumvi outcomes, findings from routine care and a simplified initial dosing schedule.</p><p>Kyverna Therapeutics (KYTX) will present one-year Phase 2 Kysa-8 findings for miv-cel in stiff person syndrome on Wednesday, followed by updated results from a physician-led Phase 1 study in progressive MS on Friday.</p><p>Immunic (IMUX) will share longer-term progressive-MS findings from Calliper on&nbsp; Wednesday. Zenas BioPharma (ZBIO) follows on Thursday with Phase 2 MS findings for Obexelimab and Orelabrutinib.</p><h2 class="st-heading-2">Huntington’s And Cancer Data Close Trading Week</h2><p>Alnylam Pharmaceuticals (ALNY) will present initial Phase 1 ALN-HTT02 results on Friday at the European Huntington’s Disease Network congress in Krakow. Developed with Regeneron, the investigational RNA-interference treatment targets huntingtin, the protein implicated in Huntington’s disease.</p><p>Tango Therapeutics (TNGX) will hold a pancreatic-cancer webcast on Friday discussing Vopimetostat combined with Daraxonrasib or Zoldonrasib. The study involves patients with MTAP-deleted, RAS-mutant cancers.&nbsp;</p><h2 class="st-heading-2"><strong>Kidney Week Puts HUMA And VERA In Focus</strong></h2><p>Humacyte (HUMA) will present interim Phase 3 V012 results on Thursday, comparing its tissue-engineered vessel with a conventional fistula for dialysis access in women with end-stage kidney disease. The company targets a supplemental FDA application this quarter.</p><p>Vera Therapeutics (VERA) will present its Origin 3 final efficacy analysis on Thursday, following the September announcement of the results. Saturday brings separate interim Phase 2 Pioneer findings in IgA nephropathy and primary membranous nephropathy.</p><p>Maze Therapeutics (MAZE) presents additional detail from its previously reported Phase 2 Horizon kidney-disease study on Saturday. Climb Bio (CLYM) presents healthy-volunteer CLYM116 findings on Thursday and preliminary Phase 2 Budoprutug results in primary membranous nephropathy on Saturday.</p><h2 class="st-heading-2"><strong>Moderna And Merck Lead ESMO’s Saturday Watchlist</strong></h2><p>ESMO opens on Friday in Madrid. Moderna (MRNA) and Merck (MRK) will present Phase 3 INTerpath-001 melanoma findings on Saturday, testing individualized treatment intismeran autogene plus Keytruda against Keytruda alone after surgery.</p><p>The companies previously announced improvements in recurrence-free and distant-metastasis-free survival. Overall-survival evaluation continues. Moderna will also host an investor webcast on Saturday.</p><p>Compass Therapeutics (CMPX) presents Companion-002 findings on Saturday. Tovecimig plus Paclitaxel improved response rates and progression-free survival in previously treated biliary tract cancer, but did not demonstrate a statistically significant overall-survival benefit. Compass says the FDA recommended another trial demonstrating a survival benefit before an application.</p><p>Immatics (IMTX) presents IMA203CD8 cell-therapy findings on Friday, followed Saturday by IMA402 bispecific data and Anzu-cel melanoma follow-up. Biohaven (BHVN), Perspective Therapeutics (CATX) and Eikon Therapeutics (EIKN) also have early-stage cancer presentations on Friday.</p><p>Additional presentations include Incyte’s (INCY) CDK2-inhibitor findings on Friday and colorectal-cancer bispecific data on Saturday, alongside Regeneron’s (REGN) final Phase 2 analysis of Cemiplimab before surgery in cutaneous squamous-cell carcinoma on Saturday.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-musk-tesla-value-optimus-cybercab-analyst-flying-halo-car-luring-buyers/cZx8eXmRBtv">TSLA Stock Rises Overnight: Musk Bets Tesla’s Value On Optimus, Cybercab — Analyst Sees Flying ‘Halo Car’ Luring Buyers&nbsp;</a></p>

In this photo illustration, silhouette of hands in medical gloves hold a medical syringe and a vial in front of Pfizer,Biontech,AstraZeneca,Moderna,Johnson & johnson,Novavax,Merck and Janssen logos. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

iShares Biotechnology ETF

Merck & Co Inc

Moderna Inc

Regeneron Pharmaceuticals, Inc.

Regenxbio Inc

TG Therapeutics Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$22.53
Prev Close	$22.23
Open	$22.38
Dividend Yield	0.00%
50-Day Moving Average	$23.62
Beta	1.36
Avg. Volume	2.99M
PE Ratio	-26.90

52-Week High	$34.39
52-Week Low	$7.37
Market Capitalization	$3.8B
EPS (Annual)	-$0.8746
Price to Book	3.70
Revenue Per Employee	$455,357.66

Feed

News

Sentiment

Earnings

Fundamentals

Info

TNGX Fundamentals